Toremifeneのソースを表示
←
Toremifene
ナビゲーションに移動
検索に移動
あなたには「このページの編集」を行う権限がありません。理由は以下の通りです:
この操作は、次のグループに属する利用者のみが実行できます:
登録利用者
。
このページのソースの閲覧やコピーができます。
{{Short description|Chemical compound}} {{Drugbox | verifiedrevid = 470611877 | IUPAC_name = 2-[4-[(1''Z'')-4-Chloro-1,2-diphenyl-but-1-en-1-yl]phenoxy]-''N'',''N''-dimethylethanamine | image = Toremifene.svg | width = 250px | image2 = Toremifene molecule ball.png | width2 = 250px <!--Clinical data--> | pronounce = {{IPAc-en|ˈ|t|ɔːr|ə|m|ɪ|f|iː|n}} | tradename = Fareston, others | Drugs.com = {{drugs.com|monograph|fareston}} | MedlinePlus = a608003 | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_category = | licence_EU = yes | legal_AU = <!-- Unscheduled / S2 / S4 / S8 --> | legal_UK = <!-- GSL / P / POM / CD --> | legal_US = <!-- OTC / Rx-only --> | legal_status = | routes_of_administration = [[Oral administration|By mouth]] | class = [[Selective estrogen receptor modulator]] <!--Pharmacokinetic data--> | bioavailability = Good/~100%<ref name="pmid11108432" /><ref name="Jr.Lawrence2015">{{cite book| vauthors = DeVita Jr VT, Lawrence TS, Rosenberg SA |title=DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology|url=https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1126|date=7 January 2015|publisher=Wolters Kluwer Health|isbn=978-1-4698-9455-3|pages=1126–}}</ref> | protein_bound = 99.7%<ref name="pmid11108432" /> | metabolism = [[Liver]] ([[CYP3A4]])<ref name="RosenthalBurchum2017" /><ref name="Jr.Lawrence2015" /> | metabolites = N-Desmethyltoremifene; 4-Hydroxytoremifene; [[Ospemifene]]<ref name="ChabnerLongo2011" /><ref name="Toremifene-Label"/> | elimination_half-life = Toremifene: 3–7 days<ref name="pmid11108432" /><br />Metabolites: 4–21 days<ref name="Jr.Lawrence2015" /><ref name="Toremifene-Label"/><ref name="pmid11108432" /> | excretion = [[Feces]]: 70% (as metabolites)<ref name="Jr.Lawrence2015" /> <!--Identifiers--> | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 89778-26-7 | CAS_supplemental = <br />89778-27-8 ([[citrate]]) | ATC_prefix = L02 | ATC_suffix = BA02 | ATC_supplemental = | PubChem = 3005573 | IUPHAR_ligand = 4325 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00539 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 2275722 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 7NFE54O27T | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D08620 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 9635 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 1655 | PDB_ligand = T0R | synonyms = (''Z'')-Toremifene; 4-Chlorotamoxifen; 4-CT; Acapodene; CCRIS-8745; FC-1157; FC-1157a; GTx-006; NK-622; NSC-613680 <!--Chemical data--> | C=26 | H=28 | Cl=1 | N=1 | O=1 | SMILES = ClCCC(/c1ccccc1)=C(/c2ccc(OCCN(C)C)cc2)c3ccccc3 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25- | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = XFCLJVABOIYOMF-QPLCGJKRSA-N }} <!-- Definition and medical uses --> '''Toremifene''', sold under the brand name '''Fareston''' among others, is a medication which is used in the treatment of [[metastatic breast cancer|advanced breast cancer]] in [[menopause|postmenopausal]] women.<ref name="Toremifene-Label">{{cite web | title = FARESTON (toremifene citrate) 60 mg Tablets oral administration | url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020497s006lbl.pdf | work = GTx, Inc. | publisher = U.S. Food and Drug Administration | date = March 2011 }}</ref><ref name="MillerIngle2002">{{cite book| vauthors = Miller WR, Ingle JN |title=Endocrine Therapy in Breast Cancer|url=https://books.google.com/books?id=00_LBQAAQBAJ&pg=PA55|date=8 March 2002|publisher=CRC Press|isbn=978-0-203-90983-6|pages=55–57}}</ref><ref name="ChabnerLongo2011">{{cite book| vauthors = Chabner BA, Longo DL |title=Cancer Chemotherapy and Biotherapy: Principles and Practice|url=https://books.google.com/books?id=0U4aj4GZWCIC&pg=PA659|date=7 December 2011|publisher=Lippincott Williams & Wilkins|isbn=978-1-4511-4820-6|pages=659–}}</ref> It is taken [[oral administration|by mouth]].<ref name="Toremifene-Label" /> <!-- Side effects --> [[Side effect]]s of toremifene include [[hot flash]]es, [[sweating]], [[nausea]], [[vomiting]], [[dizziness]], [[vaginal discharge]], and [[vaginal bleeding]].<ref name="RosenthalBurchum2017" /><ref name="SchiffArrillaga2017" /> It can also cause [[blood clot]]s, [[heart dysrhythmia|irregular heartbeat]], [[cataract]]s, [[visual disturbance]]s, [[elevated liver enzymes]], [[endometrial hyperplasia]], and [[endometrial cancer]].<ref name="RosenthalBurchum2017" /> [[Hypercalcemia|High blood calcium levels]] can occur in women with [[bone metastasis|bone metastases]].<ref name="RosenthalBurchum2017" /> <!-- Mechanism of action --> The medication is a [[selective estrogen receptor modulator]] (SERM) and hence is a mixed [[agonist]]–[[receptor antagonist|antagonist]] of the [[estrogen receptor]] (ER), the [[biological target]] of [[estrogen]]s like [[estradiol]].<ref name="RosenthalBurchum2017" /><ref name="SchiffArrillaga2017" /> It has [[estrogen (medication)|estrogen]]ic effects in [[bone]], the [[liver]], and the [[uterus]] and [[antiestrogen]]ic effects in the [[breast]]s.<ref name="MillerIngle2002" /><ref name="MorrowJordan2003" /><ref name="ScholarlyEditions2013" /><ref name="RosenthalBurchum2017" /> It is a [[triphenylethylene]] [[chemical derivative|derivative]] and is closely related to [[tamoxifen]].<ref name="CanoAlsina2006" /> <!-- History, society, and culture --> Toremifene was introduced for medical use in 1997.<ref name="SilvaZurrida2005" /><ref name="BidlackOmaye2000" /> It was the first [[antiestrogen]] to be introduced since tamoxifen in 1978.<ref name="DiSaiaCreasman2017" /> It is available as a [[generic drug|generic medication]] in the [[United States]].<ref name="Drugs.com-Generic">{{Cite news|url=https://www.drugs.com/availability/generic-fareston.html|title=Generic Fareston Availability - Drugs.com|work=Drugs.com|access-date=2019-04-19|language=en-US}}</ref> {{TOC limit|3}} ==Medical uses== Toremifene is approved for the treatment of [[metastatic breast cancer]] in postmenopausal women with [[hormone receptor positive breast tumor|estrogen receptor-positive]] or unknown-status [[tumor]]s.<ref name="Toremifene-Label" /><ref name="MillerIngle2002" /> This is its only approved use in the [[United States]].<ref name="Toremifene-Label"/> It shows equivalent effectiveness to tamoxifen for this indication.<ref name="MillerIngle2002" /><ref name="pmid18062751" /> Toremifene has been found to be effective in the treatment of [[mastalgia|breast pain]] and may be a more effective medication than tamoxifen for this indication.<ref name="BlandCopeland2017">{{cite book| vauthors = Bland KI, Copeland EM, Klimberg VS, Gradishar WJ |title=The Breast E-Book: Comprehensive Management of Benign and Malignant Diseases|url=https://books.google.com/books?id=hJwqDwAAQBAJ&pg=PA86|date=29 June 2017|publisher=Elsevier Health Sciences|isbn=978-0-323-51187-2|pages=86–}}</ref> It also has superior effects on [[bone mineral density]] and [[lipid profile]], including levels of [[cholesterol]] and [[triglyceride]]s, compared to tamoxifen.<ref name="pmid18062751" /> Toremifene has been reported to significantly improve symptoms of [[gynecomastia]] in men.<ref name="TabbalFuleihan2010">{{cite book| vauthors = Tabbal M, Fuleihan GE |title=Osteoporosis in Men |chapter=Future Therapies|year=2010|pages=713–732|doi=10.1016/B978-0-12-374602-3.00057-2|isbn=9780123746023}}</ref> ===Available forms=== Toremifene is provided in the form of 60 mg [[oral administration|oral]] [[tablet (pharmacy)|tablet]]s.<ref name="CNE2019">{{cite book| vauthors = Wirfs MJ |title=The APRN and PA's Complete Guide to Prescribing Drug Therapy 2020|url=https://books.google.com/books?id=6DiPDwAAQBAJ&pg=PA60|date=9 May 2019|publisher=Springer Publishing Company|isbn=978-0-8261-7934-0|pages=60–}}</ref><ref name="CasciatoTerrito2012">{{cite book | vauthors = Casciato DA | chapter = Chapter 4: Cancer Chemotherapeutic Agents | veditors = Casciato DA, Territo MC |title=Manual of Clinical Oncology|chapter-url=https://books.google.com/books?id=4ggoPDgZx2YC&pg=PA122|year=2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-4511-1560-4|pages=122–}}</ref> ==Side effects== The [[side effect]]s of toremifene are similar to those of tamoxifen.<ref name="RosenthalBurchum2017" /> The most common side effect is [[hot flash]]es.<ref name="RosenthalBurchum2017" /> Other side effects include [[sweating]], [[nausea]], [[vomiting]], [[dizziness]], [[vaginal discharge]], and [[vaginal bleeding]].<ref name="RosenthalBurchum2017" /><ref name="SchiffArrillaga2017">{{cite book| vauthors = Schiff D, Arrillaga I, Wen PY |title=Cancer Neurology in Clinical Practice: Neurological Complications of Cancer and its Treatment|url=https://books.google.com/books?id=wQI2DwAAQBAJ&pg=PA296|date=16 September 2017|publisher=Humana Press|isbn=978-3-319-57901-6|pages=296–}}</ref> In women with [[bone metastasis|bone metastases]], [[hypercalcemia]] may occur.<ref name="RosenthalBurchum2017" /> Toremifene has a small risk of [[thromboembolism|thromboembolic event]]s.<ref name="RosenthalBurchum2017" /> [[Cataract]]s, [[visual impairment|vision changes]], and [[elevated transaminases|elevation of liver enzymes]] have been reported.<ref name="RosenthalBurchum2017" /><ref name="SchiffArrillaga2017" /> The drug [[drug-induced QT prolongation|prolongs the QT interval]] and hence has a risk of potentially fatal [[Heart arrhythmia|dysrhythmia]]s.<ref name="RosenthalBurchum2017" /> The risk of dysrhythmias can be reduced by avoiding use in patients with [[hypokalemia]], [[hypomagnesemia]], pre-existing QT prolongation, and in those taking other QT-prolonging drugs.<ref name="RosenthalBurchum2017" /> Because toremifene has [[estrogen (medication)|estrogen]]ic actions in the [[uterus]], it can increase the risk of [[endometrial hyperplasia]] and [[endometrial cancer]].<ref name="RosenthalBurchum2017" /> Toremifene appears to be safer than tamoxifen.<ref name="pmid18062751" /> It has a lower risk of [[venous thromboembolism]] (VTE) (e.g., [[pulmonary embolism]]), [[stroke]], and [[cataract]]s.<ref name="pmid18062751" /> The lower risk of VTE may be related to the fact tamoxifen decreases levels of the [[antithrombin III]] to a significantly greater extent than either 60 or 200 mg/day toremifene.<ref name="pmid18062751" /> ==Interactions== Toremifene is a [[substrate (biochemistry)|substrate]] of [[CYP3A4]], a [[cytochrome P450]] [[enzyme]], and hence drugs that [[enzyme inducer|induce]] or [[enzyme inhibitor|inhibit]] this enzyme can respectively decrease or increase levels of toremifene in the body.<ref name="RosenthalBurchum2017" /> ==Pharmacology== ===Pharmacodynamics=== Toremifene is a [[selective estrogen receptor modulator]] (SERM).<ref name="RosenthalBurchum2017" /><ref name="SchiffArrillaga2017" /><ref name="pmid16503765">{{cite journal | vauthors = Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA | title = Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy | journal = Expert Opin Investig Drugs | volume = 15 | issue = 3 | pages = 293–305 | date = March 2006 | pmid = 16503765 | doi = 10.1517/13543784.15.3.293 | s2cid = 29510508 }}</ref> That is, it is a [[binding selectivity|selective]] mixed [[agonist–antagonist]] of the [[estrogen receptor]]s (ERs), with [[estrogen (medication)|estrogen]]ic actions in some [[tissue (biology)|tissue]]s and [[antiestrogen]]ic actions in other tissues.<ref name="RosenthalBurchum2017" /><ref name="SchiffArrillaga2017" /> The medication has estrogenic effects in [[bone]], [[partial agonist|partial]] estrogenic effects in the [[uterus]] and [[liver]], and antiestrogenic effects in the [[breast]]s.<ref name="MillerIngle2002" /><ref name="MorrowJordan2003">{{cite book| vauthors = Morrow M, Jordan VC |title=Managing Breast Cancer Risk|url=https://books.google.com/books?id=HXKibhaF5lMC&pg=PA192|year=2003|publisher=PMPH-USA|isbn=978-1-55009-260-8|pages=192–}}</ref><ref name="ScholarlyEditions2013">{{cite book|title=Selective Estrogen Receptor Modulators—Advances in Research and Application: 2013 Edition: ScholarlyBrief|url=https://books.google.com/books?id=AAzZGOf6rl0C&pg=PT51|date=1 May 2013|publisher=ScholarlyEditions|isbn=978-1-4901-0447-8|pages=51–}}</ref><ref name="RosenthalBurchum2017">{{cite book| vauthors = Rosenthal L, Burchum J |title=Lehne's Pharmacotherapeutics for Advanced Practice Providers - E-Book|url=https://books.google.com/books?id=gfYoDgAAQBAJ&pg=PA931|date=17 February 2017|publisher=Elsevier Health Sciences|isbn=978-0-323-44779-9|pages=931–}}</ref> {{Tissue-specific estrogenic and antiestrogenic activity of SERMs}} The [[affinity (pharmacology)|affinity]] of toremifene for the ER is similar to that of tamoxifen.<ref name="MillerIngle2002" /><ref name="Workman2012">{{cite book| vauthors = Workman P |title=New Approaches in Cancer Pharmacology: Drug Design and Development|url=https://books.google.com/books?id=ZLkJCAAAQBAJ&pg=PT104|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-77874-2|pages=104–}}</ref><ref name="pmid2941176">{{cite journal | vauthors = Kallio S, Kangas L, Blanco G, Johansson R, Karjalainen A, Perilä M, Pippo I, Sundquist H, Södervall M, Toivola R | title = A new triphenylethylene compound, Fc-1157a. I. Hormonal effects | journal = Cancer Chemother Pharmacol | volume = 17 | issue = 2 | pages = 103–8 | date = 1986 | pmid = 2941176 | doi = 10.1007/BF00306736 | s2cid = 13238715 }}</ref> In studies using rat ER, toremifene had about 1.4% and tamoxifen had about 1.6% of the affinity of [[estradiol (medication)|estradiol]] for the ER.<ref name="WittliffKerr2005">{{cite book | vauthors = Wittliff JL, Kerr II JL, Andres SA | year = 2005 | chapter = Estrogens IV: Estrogen-Like Pharmaceuticals | veditors = Wexler P | title = Encyclopedia of Toxicology, 2nd Edition | volume = Dib-L | pages = 254–258 | publisher = Elsevier | isbn = 9780080548005 | chapter-url = https://books.google.com/books?id=dEnbcGW44RYC&pg=PT3318}}</ref><ref name="pmid10746941">{{cite journal | vauthors = Blair RM, Fang H, Branham WS, Hass BS, Dial SL, Moland CL, Tong W, Shi L, Perkins R, Sheehan DM | title = The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands | journal = Toxicol Sci | volume = 54 | issue = 1 | pages = 138–53 | date = March 2000 | pmid = 10746941 | doi = 10.1093/toxsci/54.1.138 | doi-access = free }}</ref><ref name="pmid11258977">{{cite journal | vauthors = Fang H, Tong W, Shi LM, Blair R, Perkins R, Branham W, Hass BS, Xie Q, Dial SL, Moland CL, Sheehan DM | title = Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens | journal = Chem Res Toxicol | volume = 14 | issue = 3 | pages = 280–94 | date = March 2001 | pmid = 11258977 | doi = 10.1021/tx000208y }}</ref><ref name="pmid8142059">{{cite journal | vauthors = Chander SK, Sahota SS, Evans TR, Luqmani YA | title = The biological evaluation of novel antioestrogens for the treatment of breast cancer | journal = Crit Rev Oncol Hematol | volume = 15 | issue = 3 | pages = 243–69 | date = December 1993 | pmid = 8142059 | doi = 10.1016/1040-8428(93)90044-5 }}</ref><ref name="KavlockDaston2012">{{cite book| vauthors = Kavlock RJ, Daston GP |title=Drug Toxicity in Embryonic Development II: Advances in Understanding Mechanisms of Birth Defects: Mechanistics Understanding of Human Development Toxicants|url=https://books.google.com/books?id=vcHsCAAAQBAJ&pg=PA437|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-60447-8|pages=437–}}</ref><ref name="pmid2941176" /> The affinities (K<sub>i</sub>) of toremifene at the human ERs have been reported as 20.3 ± 0.1 nM for the [[ERα]] and 15.4 ± 3.1 nM for the [[ERβ]].<ref name="pmid16503765" /> In other rat ER studies, toremifene had 3–9% of the affinity of estradiol for the ER while its [[metabolite]]s ''N''-desmethyltoremifene and 4-hydroxytoremifene had 3–5% and 64–158% of the affinity of estradiol for the ER, respectively.<ref name="pmid2147128">{{cite journal | vauthors = Kangas L | title = Biochemical and pharmacological effects of toremifene metabolites | journal = Cancer Chemother Pharmacol | volume = 27 | issue = 1 | pages = 8–12 | date = 1990 | pmid = 2147128 | doi = 10.1007/BF00689269 | s2cid = 11502291 }}</ref><ref name="pmid2149286">{{cite journal | vauthors = Robinson SP, Parker CJ, Jordan VC | title = Preclinical studies with toremifene as an antitumor agent | journal = Breast Cancer Res Treat | volume = 16 | issue = Suppl | pages = S9–17 | date = August 1990 | pmid = 2149286 | doi = 10.1007/BF01807139 | s2cid = 19989845 }}</ref><ref name="Osborne2012">{{cite book| vauthors = Osborne CK |title=Endocrine Therapies in Breast and Prostate Cancer|url=https://books.google.com/books?id=gW0eBAAAQBAJ&pg=PA104|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4613-1731-9|pages=104–}}</ref> The affinity of another metabolite, 4-hydroxy-''N''-desmethyltoremifene, was not assessed.<ref name="pmid2149286" /> 4-Hydroxytoremifene showed about 100-fold higher antiestrogenic [[potency (pharmacology)|potency]] than toremifene ''[[in vitro]]'' in one study,<ref name="pmid2149286" /> but not in another.<ref name="pmid2147128"/> 4-Hydroxy-''N''-desmethyltoremifene has also been found to be strongly antiestrogenic ''in vitro''.<ref name="pmid2147128" /> The metabolites of toremifene, particularly 4-hydroxytoremifene, may contribute importantly to the clinical activity of the medication.<ref name="pmid11108432" /><ref name="pmid2149286" /><ref name="pmid2147128" /> On the other hand, some authorities consider toremifene not to be a [[prodrug]].<ref name="pmid24439786">{{cite journal | vauthors = Vogel CL, Johnston MA, Capers C, Braccia D | title = Toremifene for breast cancer: a review of 20 years of data | journal = Clin Breast Cancer | volume = 14 | issue = 1 | pages = 1–9 | date = February 2014 | pmid = 24439786 | doi = 10.1016/j.clbc.2013.10.014 | doi-access = free }}</ref> Toremifene is very similar to [[tamoxifen]] and shares most of its properties.<ref name="MillerIngle2002" /><ref name="MorrowJordan2003" /><ref name="ScholarlyEditions2013" /><ref name="RosenthalBurchum2017" /> There are some indications that toremifene may be safer than tamoxifen as it is not a [[wikt:hepatocarcinogen|hepatocarcinogen]] in animals and may have less potential for [[genotoxicity]].<ref name="MillerIngle2002" /><ref name="ChabnerLongo2011" /> However, clinical studies have found no significant differences between toremifene and tamoxifen, including in terms of [[effectiveness]], [[tolerability]], and [[drug safety|safety]], and hence the clinical use of toremifene has been somewhat limited.<ref name="MillerIngle2002" /><ref name="ChabnerLongo2011" /> Toremifene is thought to have about one-third of the [[potency (pharmacology)|potency]] of tamoxifen; i.e., 60 mg toremifene is roughly equivalent to 20 mg tamoxifen in the treatment of breast cancer.<ref name="pmid9647865">{{cite journal | vauthors = MacGregor JI, Jordan VC | title = Basic guide to the mechanisms of antiestrogen action | journal = Pharmacol. Rev. | volume = 50 | issue = 2 | pages = 151–96 | date = June 1998 | pmid = 9647865 | url = http://pharmrev.aspetjournals.org/content/50/2/151.short}}</ref> Toremifene has been found to have [[antigonadotropic]] effects in postmenopausal women,<ref name="pmid14692654">{{cite journal | vauthors = Ellmén J, Hakulinen P, Partanen A, Hayes DF | title = Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients | journal = Breast Cancer Res. Treat. | volume = 82 | issue = 2 | pages = 103–11 | date = November 2003 | pmid = 14692654 | doi = 10.1023/B:BREA.0000003957.54851.11 | url =https://deepblue.lib.umich.edu/bitstream/2027.42/44217/1/10549_2004_Article_5150739.pdf | hdl = 2027.42/44217 | s2cid = 207694212 | hdl-access = free }}</ref> [[progonadotropic]] effects in men,<ref name="pmid18692782">{{cite journal | vauthors = Tsourdi E, Kourtis A, Farmakiotis D, Katsikis I, Salmas M, Panidis D | title = The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia | journal = Fertil. Steril. | volume = 91 | issue = 4 Suppl | pages = 1427–30 | date = April 2009 | pmid = 18692782 | doi = 10.1016/j.fertnstert.2008.06.002 | doi-access = free }}</ref> to increase [[sex hormone-binding globulin]] levels,<ref name="pmid14692654" /> and to decrease [[insulin-like growth factor 1]] levels by about 20% in postmenopausal women and men.<ref name="pmid29383334">{{cite journal | vauthors = Roelfsema F, Yang RJ, Takahashi PY, Erickson D, Bowers CY, Veldhuis JD | title = Effects of Toremifene, a Selective Estrogen Receptor Modulator, on Spontaneous and Stimulated GH Secretion, IGF-I, and IGF-Binding Proteins in Healthy Elderly Subjects | journal = Journal of the Endocrine Society| volume = 2 | issue = 2 | pages = 154–165 | date = February 2018 | pmid = 29383334 | pmc = 5789038 | doi = 10.1210/js.2017-00457 }}</ref> In addition to its activity as a SERM, 4-hydroxytoremifene is an antagonist of the [[estrogen-related receptor γ]] (ERRγ).<ref name="pmid16515477">{{cite journal | vauthors = Ariazi EA, Jordan VC | title = Estrogen-related receptors as emerging targets in cancer and metabolic disorders | journal = Curr Top Med Chem | volume = 6 | issue = 3 | pages = 203–15 | date = 2006 | pmid = 16515477 | doi = 10.2174/1568026610606030203 }}</ref> ===Pharmacokinetics=== ====Absorption==== The [[bioavailability]] of toremifene has not been precisely determined but is known to be good and has been estimated to be approximately 100%.<ref name="pmid11108432" /><ref name="Jr.Lawrence2015" /> Levels of toremifene at [[steady state levels|steady state]] with a dosage of 60 mg/day are 800 to 879 ng/mL.<ref name="pmid11108432" /> Levels of ''N''-desmethyltoremifene at steady state with toremifene were 3,058 ng/mL at 60 mg/day, 5,942 ng/mL at 200 mg/day, and 11,913 ng/mL at 400 mg/day.<ref name="pmid11108432" /> Levels of 4-hydroxytoremifene at steady state with toremifene were 438 ng/mL at 200 mg/day and 889 ng/mL at 400 mg/day.<ref name="pmid11108432" /> Concentrations of toremifene increase linearly across a dose range of 10 to 680 mg.<ref name="pmid22356442">{{cite journal | vauthors = Gennari L, Merlotti D, Stolakis K, Nuti R | title = Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis | journal = Expert Opin Drug Metab Toxicol | volume = 8 | issue = 4 | pages = 505–13 | date = April 2012 | pmid = 22356442 | doi = 10.1517/17425255.2012.665873 | s2cid = 19547631 }}</ref><ref name="pmid2142247">{{cite journal | vauthors = Anttila M, Valavaara R, Kivinen S, Mäenpää J | title = Pharmacokinetics of toremifene | journal = J Steroid Biochem | volume = 36 | issue = 3 | pages = 249–52 | date = June 1990 | pmid = 2142247 | doi = 10.1016/0022-4731(90)90019-o }}</ref> ====Distribution==== Toremifene is 99.7% [[plasma protein binding|bound to plasma protein]]s, with 92% bound specifically to [[human serum albumin|albumin]], about 6% to [[beta-1 globulin|β<sub>1</sub> globulin]] fraction, and about 2% to a fraction between albumin and [[alpha-1 globulin|α<sub>1</sub> globulin]]s.<ref name="pmid22356442" /><ref name="pmid11108432">{{cite journal | vauthors = Taras TL, Wurz GT, Linares GR, DeGregorio MW | title = Clinical pharmacokinetics of toremifene | journal = Clin Pharmacokinet | volume = 39 | issue = 5 | pages = 327–34 | date = November 2000 | pmid = 11108432 | doi = 10.2165/00003088-200039050-00002 | s2cid = 26647296 }}</ref> The apparent [[volume of distribution]] of toremifene ranged from 457 to 958 L.<ref name="pmid22356442" /> ====Metabolism==== Toremifene is [[metabolism|metabolized]] in the [[liver]] primarily by [[CYP3A4]] and then undergoes secondary [[hydroxylation]].<ref name="Jr.Lawrence2015" /> The [[metabolite]]s of toremifene include ''N''-desmethyltoremifene, 4-hydroxytoremifene, and 4-hydroxy-''N''-desmethyltoremifene, among others.<ref name="pmid11108432" /><ref name="pmid2149286" /><ref name="Jr.Lawrence2015" /><ref name="BrennerStevens2017">{{cite book| vauthors = Brenner GM, Stevens C |title=Brenner and Stevens' Pharmacology E-Book|url=https://books.google.com/books?id=v3g4DwAAQBAJ&pg=PA394|date=28 September 2017|publisher=Elsevier Health Sciences|isbn=978-0-323-39172-6|pages=394–}}</ref> [[Ospemifene]] (deaminohydroxytoremifene) is also a major metabolite of toremifene.<ref name="pmid11108432" /><ref name="Toremifene-Label"/> ====Elimination==== The [[elimination half-life]] of toremifene is 3 to 7 days in healthy individuals.<ref name="pmid11108432" /> In people with [[impaired liver function]], the half-life is 11 days.<ref name="pmid11108432" /> The elimination half-lives of the metabolites of toremifene are 5 to 21 days for ''N''-desmethyltoremifene, 5 days for 4-hydroxytoremifene, and 4 days for ospemifene.<ref name="pmid11108432" /><ref name="Jr.Lawrence2015" /><ref name="Toremifene-Label"/> The long elimination half-lives of toremifene and its metabolites are thought to be due to [[enterohepatic recirculation]] and high plasma protein binding.<ref name="pmid11108432" /><ref name="RosenthalBurchum2017" /> Toremifene is [[elimination (pharmacology)|eliminated]] 70% in the [[feces]], as metabolites.<ref name="Jr.Lawrence2015" /> ==Chemistry== {{See also|List of selective estrogen receptor modulators|Triphenylethylene}} Toremifene, also known as ''4-chlorotamoxifen'', is a [[chemical derivative|derivative]] of [[triphenylethylene]] and a close [[structural analog|analogue]] of [[tamoxifen]].<ref name="CanoAlsina2006">{{cite book| vauthors = Cano A, Calaf i Alsina J, Duenas-Diez JL |title=Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs|url=https://books.google.com/books?id=heJDAAAAQBAJ&pg=PA52|date=22 September 2006|publisher=Springer Science & Business Media|isbn=978-3-540-34742-2|pages=52–}}</ref> It is also closely related to [[afimoxifene]] (4-hydroxytamoxifen) and [[ospemifene]] (deaminohydroxytoremifene).<ref name="Weber2015">{{cite book| vauthors = Weber GF |title=Molecular Therapies of Cancer|url=https://books.google.com/books?id=dhs_CgAAQBAJ&pg=PA304|date=22 July 2015|publisher=Springer|isbn=978-3-319-13278-5|pages=304–}}</ref><ref name="MaximovMcDaniel2013">{{cite book| vauthors = Maximov PY, McDaniel RE, Jordan VC |title=Tamoxifen: Pioneering Medicine in Breast Cancer |url= https://books.google.com/books?id=p-W5BAAAQBAJ&pg=PA170 |date=23 July 2013 |publisher=Springer Science & Business Media |isbn=978-3-0348-0664-0 |pages=170–}}</ref> ==History== Toremifene was introduced in the [[United States]] in 1997.<ref name="SilvaZurrida2005">{{cite book| vauthors = Silva OE, Zurrida S |title=Breast Cancer: A Practical Guide|url=https://books.google.com/books?id=fqZqYKQLzfMC&pg=PA355|year=2005|publisher=Elsevier Health Sciences|isbn=0-7020-2744-8|pages=355–}}</ref><ref name="BidlackOmaye2000">{{cite book| vauthors = Bidlack WR, Omaye ST, Meskin MS, Topham DK |title=Phytochemicals as Bioactive Agents|url=https://books.google.com/books?id=-3DwAnmgyFYC&pg=PA26|date=16 March 2000|publisher=CRC Press|isbn=978-1-56676-788-0|pages=26–}}</ref> It was the first [[antiestrogen]] to be introduced in this country since tamoxifen in 1978.<ref name="DiSaiaCreasman2017">{{cite book| vauthors = DiSaia PJ, Creasman WT, Mannel RS, McMeekin DS, Mutch DG |title=Clinical Gynecologic Oncology E-Book|url=https://books.google.com/books?id=MkoQDgAAQBAJ&pg=PA124|date=4 February 2017|publisher=Elsevier Health Sciences|isbn=978-0-323-44316-6|pages=124–}}</ref> ==Society and culture== ===Generic names=== ''Toremifene'' is the [[generic term|generic name]] of the drug and its {{abbrlink|INN|International Nonproprietary Name}} and {{abbrlink|BAN|British Approved Name}}, while ''toremifene citrate'' is its {{abbrlink|USAN|United States Adopted Name}} and {{abbrlink|JAN|Japanese Accepted Name}} and ''torémifène'' is its {{abbrlink|DCF|Dénomination Commune Française}}.<ref name="Elks2014">{{cite book| vauthors = Elks J |title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1222|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=1222–}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA1048|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=1048–}}</ref><ref name="MortonHall2012">{{cite book| vauthors = Morton IK, Hall JM |title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA277|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=277–}}</ref><ref name="Drugs.com">{{Cite news|url=https://www.drugs.com/international/toremifene.html|title=Toremifene - Drugs.com|work=Drugs.com|access-date=2018-02-08|language=en-US}}</ref> ===Brand names=== Toremifene is marketed almost exclusively under the brand name Fareston.<ref name="IndexNominum2000" /><ref name="Drugs.com" /> ===Availability=== Toremifene is marketed widely throughout the world and is available in the [[United States]], the [[United Kingdom]], [[Ireland]], many other [[Europe]]an countries, [[South Africa]], [[Australia]], [[New Zealand]], and elsewhere throughout the world.<ref name="IndexNominum2000" /><ref name="Drugs.com" /> ==Research== Toremifene was also evaluated for prevention of [[prostate cancer]] and had the tentative brand name Acapodene.<ref>{{cite journal | vauthors = Price N, Sartor O, Hutson T, Mariani S | year = 2005 | title = Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer | journal = Clin Prostate Cancer | volume = 3 | issue = 4| pages = 211–4 | pmid = 15882476 | doi = 10.1016/s1540-0352(11)70089-0 }}</ref> In 2007 the pharmaceutical company [[Gtx inc|GTx, Inc]] was conducting two different phase 3 [[clinical trial]]s; First, a pivotal Phase clinical trial for the treatment of serious side effects of [[androgen deprivation therapy]] (ADT) (especially vertebral/spine fractures and [[hot flashes]], lipid profile, and [[gynecomastia]]) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade [[prostatic intraepithelial neoplasia]], or PIN. Results of these trials are expected by first quarter of 2008<ref>{{cite press release | title = GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review | publisher = GTx Inc. | date = 2007-07-12 | url = http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-newsArticle&ID=1025420&highlight= | access-date = 2006-07-14 }}</ref> An NDA for the first application (relief of prostate cancer ADT side effects) was submitted in Feb 2009,<ref>{{cite press release | title = GTx Announces Toremifene 80 mg NDA Accepted for Review by FDA | url = http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-newsArticle&ID=1257471&highlight= }}</ref> and in Oct 2009 the FDA said they would need more clinical data, e.g. another phase III trial.<ref>{{cite web |url=http://www.genengnews.com/gen-news-highlights/gtx-and-ipsen-end-prostate-cancer-collaboration-due-to-costs-of-fda-requested-phase-iii-study/81244761/ |title=GTx and Ipsen End Prostate Cancer Collaboration due to Costs of FDA-Requested Phase III Study |date=2 Mar 2011 }}</ref> Ultimately, development was discontinued and toremifene was never marketed for complications associated with ADT or the treatment or prevention of prostate cancer.<ref name="AdisInsight">{{Cite web|url=http://adisinsight.springer.com/drugs/800004087|title=Toremifene - AdisInsight|website=adisinsight.springer.com|language=en|access-date=2018-02-08}}</ref> Toremifene may be useful in the prevention of [[bicalutamide]]-induced gynecomastia.<ref name="pmid18062751">{{cite journal | vauthors = Sieber PR | title = Treatment of bicalutamide-induced breast events | journal = Expert Rev Anticancer Ther | volume = 7 | issue = 12 | pages = 1773–9 | date = December 2007 | pmid = 18062751 | doi = 10.1586/14737140.7.12.1773 | s2cid = 40410461 }}</ref> === Phase III Trial Results === A double-blind, placebo-controlled, randomized, 3 year clinical trial of toremifene was conducted using a sample of 1,260 men. Subjects had a median age of 64 years and were diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN), which is considered premalignant, though Thompson and Leach feel a low grade PIN could also be deemed premalignant.<ref>Thompson Jr, I. M., and Leach, R., Prostate cancer and prostatic intraepithelial neoplasia: true, true, and unrelated? ''J Clin Oncol,'' 2013;31:515-6. https://ascopubs.org/doi/full/10.1200/JCO.2012.46.6151={{Dead link|date=April 2023 |bot=InternetArchiveBot |fix-attempted=yes }} Retrieved 31 July 2019</ref> The sponsor, GTx, who designed and managed the study, found 34.7% of the placebo and 32.3% of the toremifene groups had cancer events. No distinction was found in [[Gleason score]]s of either group.<ref>Taneja, S. S., Morton, R., Barnette, G., Sieber, P., Hancock, M. L., and Steiner, M., Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene ''J Clin Oncol,'' 2013;31:523-9. https://ascopubs.org/doi/abs/10.1200/JCO.2012.41.7634={{Dead link|date=April 2023 |bot=InternetArchiveBot |fix-attempted=yes }} Retrieved 31 July 2019</ref> Previous murine studies using transgenic adenocarcinoma of mouse prostate (TRAMP) mice showed toremifene prevented palpable tumors in 60% of the animals. This study used toremifene as an early prophylactic, which differentiates it from the phase III human studies.<ref>Raghow, S., Hooshdaran, M. Z., Katiyar, S., and Steiner, M. S., Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. ''Cancer Research'' 2002;62:1370-6. http://cancerres.aacrjournals.org/content/62/5/1370= Retrieved 31 July 2019</ref> ==References== {{Reflist}} ==Further reading== {{refbegin|30em}} * {{cite journal | vauthors = Taras TL, Wurz GT, Linares GR, DeGregorio MW | title = Clinical pharmacokinetics of toremifene | journal = Clin Pharmacokinet | volume = 39 | issue = 5 | pages = 327–34 | year = 2000 | pmid = 11108432 | doi = 10.2165/00003088-200039050-00002 | s2cid = 26647296 }} * {{cite journal | vauthors = Harvey HA, Kimura M, Hajba A | title = Toremifene: an evaluation of its safety profile | journal = Breast | volume = 15 | issue = 2 | pages = 142–57 | year = 2006 | pmid = 16289904 | doi = 10.1016/j.breast.2005.09.007 }} * {{cite journal | vauthors = Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA | title = Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy | journal = Expert Opin Investig Drugs | volume = 15 | issue = 3 | pages = 293–305 | year = 2006 | pmid = 16503765 | doi = 10.1517/13543784.15.3.293 | s2cid = 29510508 }} * {{cite journal | vauthors = Zhou WB, Ding Q, Chen L, Liu XA, Wang S | title = Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials | journal = Breast Cancer Res. Treat. | volume = 128 | issue = 3 | pages = 625–31 | year = 2011 | pmid = 21553116 | doi = 10.1007/s10549-011-1556-5 | s2cid = 36985808 }} * {{cite journal | vauthors = Gennari L, Merlotti D, Stolakis K, Nuti R | title = Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis | journal = Expert Opin Drug Metab Toxicol | volume = 8 | issue = 4 | pages = 505–13 | year = 2012 | pmid = 22356442 | doi = 10.1517/17425255.2012.665873 | s2cid = 19547631 }} * {{cite journal | vauthors = Mao C, Yang ZY, He BF, Liu S, Zhou JH, Luo RC, Chen Q, Tang JL | title = Toremifene versus tamoxifen for advanced breast cancer | journal = Cochrane Database Syst Rev | issue = 7 | pages = CD008926 | year = 2012 | volume = 2021 | pmid = 22786516 | doi = 10.1002/14651858.CD008926.pub2 | pmc = 8407374 }} * {{cite journal | vauthors = Vogel CL, Johnston MA, Capers C, Braccia D | title = Toremifene for breast cancer: a review of 20 years of data | journal = Clin. Breast Cancer | volume = 14 | issue = 1 | pages = 1–9 | year = 2014 | pmid = 24439786 | doi = 10.1016/j.clbc.2013.10.014 | doi-access = free }} * {{cite journal | vauthors = Mustonen MV, Pyrhönen S, Kellokumpu-Lehtinen PL | title = Toremifene in the treatment of breast cancer | journal = World J Clin Oncol | volume = 5 | issue = 3 | pages = 393–405 | year = 2014 | pmid = 25114854 | pmc = 4127610 | doi = 10.5306/wjco.v5.i3.393 | doi-access = free }} {{refend}} ==External links== * [http://adisinsight.springer.com/drugs/800004087 Toremifene - AdisInsight] {{Estrogens and antiestrogens}} {{Estrogen receptor modulators}} [[Category:Dimethylamino compounds]] [[Category:Hepatotoxins]] [[Category:Hormonal antineoplastic drugs]] [[Category:Organochlorides]] [[Category:Phenol ethers]] [[Category:Prodrugs]] [[Category:Progonadotropins]] [[Category:Selective estrogen receptor modulators]] [[Category:Triphenylethylenes]]
Toremifene
に戻る。
ナビゲーション メニュー
個人用ツール
ログイン
名前空間
ページ
日本語
表示
閲覧
履歴表示
その他
検索
案内
索引
脳科学辞典について
最近完成した項目
編集履歴
執筆にあたって
引用の仕方
著作権について
免責事項
問い合わせ
各学会編集のオンライン用語辞典
About us (in English)
Twitter (BrainScienceBot)
ツール
リンク元
関連ページの更新状況
特別ページ
ページ情報
他のプロジェクト